目的 探讨哌柏西利致不良反应的发生规律和临床表现特点，为其临床安全用药提供参考。方法 检索中国知网、万方数据、维普网、PubMed、Web of Science文献数据库中建库至2023年12月哌柏西利致不良反应案例报道并进行统计分析。结果 纳入文献40篇，涉及患者44例，均为女性且以60岁以上患者居多；发生时间为用药后1 d～15个月，主要集中在前3个月内（63.64%）；累及皮肤、呼吸系统、血液系统、神经系统等全身多个器官/系统。33例患者经停药和/或对症处理后好转，6例患者死亡，可见其潜在的致死风险。结论 临床工作者应重视哌柏西利致不良反应的危害性，加强患者用药监护，确保临床用药安全。

Objective To investigate the occurrence pattern and clinical manifestation characteristics of adverse drug reactions caused by palbociclib, and to provide reference for its safe clinical use. Methods Case reports of adverse reactions caused by palbociclib were retrieved from CNKI, Wanfang Data, VIP, PubMed, and Web of Science literature databases from December 2023 and analyzed statistically. Results Forty literatures were included, involving 44 patients, all of whom were female and most of whom were over 60 years old. The occurrence time was from 1 d to 15 months after medication, mainly in the first 3 months (63.64%). Involving skin, respiratory system, blood system, nervous system and other body organs/systems. 33 patients improved after drug withdrawal and/or symptomatic management, and 6 patients died, indicating the potential risk of death. Conclusion Clinical workers should pay attention to the danger of adverse drug reactions caused by palbociclib, strengthen the monitoring of patients' medication, and ensure the safety of clinical medication.

R979.1

国家自然科学基金资助项目（82060674）